Details for Patent: 11,123,287
✉ Email this page to a colleague
Which drugs does patent 11,123,287 protect, and when does it expire?
Patent 11,123,287 protects VYBRIQUE and is included in one NDA.
This patent has twelve patent family members in eleven countries.
Summary for Patent: 11,123,287
| Title: | Orodispersible films having quick dissolution times for therapeutic and food use |
| Abstract: | The present invention concerns an orodispersible self-supporting film free from hydrocolloids comprising: a) a film-forming substance consisting of a maltodextrin in an amount comprised between 40 and 80% by weight; b) a plasticizer in an amount comprised between 15 and 55% by weight; e) a surfactant System in an amount comprised between 0.5 and 6% by weight; d) an active ingredient for food or therapeutic use in an amount between 0.05 and 30% by weight, characterised in that it contains a homopolymer or a copolymer of vinyl acetate in a quantity comprised between 2 and 10% by weight where the percentages are calculated on the total weight of said film. |
| Inventor(s): | Francesco Cilurzo, Maurizio Di Grigoli, Paola Minghetti, Stefania Pagani |
| Assignee: | PHARMAFILM Srl |
| Application Number: | US14/430,255 |
|
Patent Claim Types: see list of patent claims | Composition; Compound; Process; |
| Patent landscape, scope, and claims: |
More… ↓ |
Drugs Protected by US Patent 11,123,287
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ibsa | VYBRIQUE | sildenafil citrate | FILM;ORAL | 210858-001 | Dec 16, 2025 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Ibsa | VYBRIQUE | sildenafil citrate | FILM;ORAL | 210858-002 | Dec 16, 2025 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Ibsa | VYBRIQUE | sildenafil citrate | FILM;ORAL | 210858-003 | Dec 16, 2025 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Ibsa | VYBRIQUE | sildenafil citrate | FILM;ORAL | 210858-004 | Dec 16, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,123,287
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Canada | 2886086 | ⤷ Start Trial | |||
| China | 104884041 | ⤷ Start Trial | |||
| Denmark | 2900215 | ⤷ Start Trial | |||
| European Patent Office | 2900215 | ⤷ Start Trial | |||
| Spain | 2640729 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
